Tagged with AstraZeneca,

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…

Serbia By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s. Country Director Ksenija Purkovic discusses the future of the Anglo-Swedish outfit, and how best to navigate a market that is…

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…

Bulgaria Zoya Paunova, country director at AstraZeneca Bulgaria, explains how a great combination of an innovative product portfolio with a skilled and dedicated team has turned the local offering into leading brands in the Bulgarian pharmaceutical market and highlights that AstraZeneca’s CSR initiatives are now ranked as the best in Europe.…

Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…

Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research.   Hong Kong is an important piece of our global R&D landscape Scott…

Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…